RNS Number : 3440Z
  Arthro Kinetics plc
  18 July 2008
   



    


    Japanese Submission for CaReS� Clinical Studies

    
FRIDAY, 18th July 2008 * Arthro Kinetics plc (AIM: AKI) (*Arthro Kinetics* or the *Company*), the orthopedics company dedicated to
regenerating joint mobility and spinal disc function announces that PolarisRx, Arthro Kinetics* joint venture partner has successfully
completed and submitted its Kakunin Shinsei to the Japanese Ministry of Health and Welfare seeking approval to begin clinical studies for
CaRaS� in Japan.

    
In addition, Arthro Kinetics* joint venture partner in China, Arthro-ANDA Tinajin Biologics Technology Co. (*AATBT*), has received a grant
from the Special Funds for Technology Innovation of Tianjin Municipal Government, for a sum of RMB 8 million (EUR740,000). These monies will
be used by AATBT to advance CaReS� into clinical studies in China in the second half of 2008.
 
Jason Loveridge, CEO of Arthro Kinetics comments; *These are both important events for AKI signaling the advancement of our autologous
chrondrocyte implant - CaReS� - into clinical studies in important markets for the Company and the continuing success of our joint ventures
in Japan & China.*


    CONTACTS 

    
 Arthro Kinetics Plc                       Tel:  +49 (0)711 305 110 70
 Jason Loveridge, Chief Executive Officer                             
 Doug Quinn, Chief Financial Officer                                  
                                                                      
 Nomura Code Securities Limited             Tel:  +44 (0)207  776 1200
 Richard Potts                                                        

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCGUUGCMUPRGAM
Arthro Kinetics (LSE:AKI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Arthro Kinetics Charts.
Arthro Kinetics (LSE:AKI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Arthro Kinetics Charts.